Original Article Effect of prostaglandin E1 in patients with advanced lung cancer treated with chemotherapy

Hai-Xia Ren, Lian-Tian Tian, Liang Zhang, Bo Yang, Lei Li, Ming-Jiang Li, Wei-Dong Zhang, Xiao-Ping Li
2018 Int J Clin Exp Med   unpublished
To examine potential VTE risk reducing effect of prostaglandin E1 (PGE1) as supplemental therapy in patients with advanced lung cancer treated by chemotherapy.68 patients were recruited in this study: 46 males with age range from 58-85 and the average age of 67.48 ± 6.06; 22 females with age range from 55-85 and the average age of 68.05 ± 7.72. All patients were randomly assigned into three groups. Patients in the therapy group (33 patients) only received chemotherapy. On the other hand,
more » ... other hand, patients in experimental group (25 patients) received combination therapy with chemotherapy and intravenous injection of PGE1 (Alprostadil, produced by Beijing Tide Pharmaceutical company) for 14 days. While in the control group (10 patients), only the supportive therapy was given. All patients were followed up till the end of their lives, with the exact time of death recorded, among which 51 died in our hospital, the rest were informed by phone calls to confirm the exact time of death. The median survival time was 61 days in the experimental group, which was not statistically significant to those of control group (52.5 days, p=0.237) and therapy group (56 days, p=0.656). In the therapy group, 9 cases showed small amount of VTE during treatment, one patient died because of fatal pulmonary embolism. In experimental group, only 2 cases experienced non-fatal VTE. The main adverse reaction of PGE1 was nodular vasculitis in 3 cases which was well tolerated. Concomitant application of PGE1 with chemotherapy significantly reduced the risk of VTE in patients with advanced lung cancer while it did not extend the patients' survival time.